Share
Hilton Mervis, Daniel s father and partner in a law firm, welcomed the report, saying: This is the first occasion when a university has been required to take a holistic look at its drug misuse policy. Hopefully it will be the catalyst for significant but easy changes which involve students and universities working together to prevent future deaths. At the heart of this is allowing students to get help for themselves or their friends without automatic sanction. The scale and impact of drug misuse and addiction in those failing to complete the university degrees or dying will never be known until there is a more open and honest dialogue within universities.
Search jobs Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board
Destiny Pharma Plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today announces the appointment of Professor Mark Wilcox to its Scientific Advisory Board (SAB).
Professor Wilcox is a consultant microbiologist and Head of R&D in Microbiology at the Leeds Teaching Hospitals and is Lead on Clostridium difficile infection for Public Health England (PHE). He also has advisory roles to UK SAGE (COVID-19), NHS England’s Infection Prevention & Control national team and PHE’s Rapid Review Panel (reviewing the utility of infection prevention and control products for the NHS), and is a member of the UK NHS Antimicrobial Resistance Programme Board.